Novartis’ Kymriah shows benefit in follicular lymphoma patients
Kymriah is the first CAR-T cell therapy to receive the FDA approval. Credit: Arek Socha from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more